What is Travere Therapeutics, Inc.'s royalty expense?

Travere Therapeutics, Inc. (TVTX) reported royalty expense of $24.82M in Q1 2026.

Travere Therapeutics, Inc. TVTX Royalty expense

Royalty expense at other companies

Ondas, Inc. ONDS

$85.5K+23.5%

HasbroHAS

$77.7M+36.3%

Ondas, Inc. ONDS

$85.5K+23.5%

SEI InvestmentsSEIC

$9.93M+9.4%

TEC

Bio-TechneTECH

$4.97M-1.4%

HasbroHAS

-$13M-54.8%

Segments

By segment

See full

Reportable Segment$24.82M+99.7%

Other financials

Income statement

See full

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.13B+72.3%

Enterprise value$5.07B+65.5%

P/S9.6×-1.3×

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RoyaltyExpense.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s royalty expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s royalty expense?: Travere Therapeutics, Inc. (TVTX) reported royalty expense of $24.82M in Q1 2026.